Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT-EN5/GOG-3055/SIENDO): Impact of subgroup analysis and molecular classification.
Pharmacology, Toxicology and Pharmaceutical Science
1
7%
Biochemistry, Genetics and Molecular Biology
1
7%
Unknown
7
47%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 32. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 November 2023.
All research outputs
#1,195,827
of 24,807,923 outputs
Outputs from Journal of Clinical Oncology
#2,957
of 21,674 outputs
Outputs of similar age
#27,390
of 435,071 outputs
Outputs of similar age from Journal of Clinical Oncology
#95
of 906 outputs
Altmetric has tracked 24,807,923 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 21,674 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.7. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 435,071 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 906 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.
